KRAS and pancreatic neoplasm: Having observed that loss of WT KRAS in the context of mutated KrasG12D was not sufficient to drive PDAC in isolation, we next determined whether additional mutations in other canonical tumor suppressors might allow escape from the observed growth arrest–like phenotype and drive more penetrant pancreatic cancer.